Publication:
Cd56 and smooth muscle actin immunoreactivity in basal cell carcinomas: Are they indicators of differentiation or do they hold a diagnostic use?

dc.contributor.authorYirmibeş, Selin
dc.contributor.buuauthorAdım, Şaduman Balaban
dc.contributor.buuauthorBALABAN ADIM, ŞADUMAN
dc.contributor.buuauthorSaraydaroğlu, Özlem
dc.contributor.buuauthorSARAYDAROĞLU, ÖZLEM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
dc.date.accessioned2024-10-22T12:38:47Z
dc.date.available2024-10-22T12:38:47Z
dc.date.issued2022-09-21
dc.description.abstractBackground Basal cell carcinoma (BCC) is the most common cutaneous malignancy and may show various differentiations. The possible pluripotent stem cell lineage of BCCs, whose origins are controversial today, is thought to be the main reason for the different morphologies. The aim of the study is to evaluate the expression of some neuroendocrine and smooth muscle markers of differentiation in BCCs and investigate the relationship between histopathologic subtypes and recurrence. Methods A total of 128 cases diagnosed as BCC in our center were included. Immunohistochemical studies of CD56, synaptophysin, chromogranin-A, smooth muscle actin (SMA), desmin, caldesmon, and Ki67 were applied. Results CD56, chromogranin-A, and synaptophysin immunoreactivity were detected in 77.3%, 13.3%, and 0.8% of the cases, respectively. 78.1% showed SMA positivity while no tumor expressed desmin or caldesmon. A correlation between histopathologic recurrence risk groups and CD56 expression was found (p < 0.05). Conclusions CD56 and SMA immunoreactivity is present in the majority of BCCs. However, the available findings do not support neuroendocrine or smooth muscle differentiation. CD56 antigen can be used for prognostic purposes in detecting high recurrence risk tumors. After the investigation of the expression rates of these two antigens in different cutaneous tumors, it may be appropriate to use them for diagnostic purposes in BCCs.
dc.identifier.doi10.1111/cup.14322
dc.identifier.endpage61
dc.identifier.issn0303-6987
dc.identifier.issue1
dc.identifier.startpage56
dc.identifier.urihttps://doi.org/10.1111/cup.14322
dc.identifier.urihttps://hdl.handle.net/11452/46858
dc.identifier.volume50
dc.identifier.wos000855979900001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley
dc.relation.journalJournal Of Cutaneous Pathology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNeuro-endocrine differentiation
dc.subjectAdhesion molecule
dc.subjectExpression
dc.subjectInvasion
dc.subjectMarkers
dc.subjectCancer
dc.subjectBasal cell carcinoma
dc.subjectCd56
dc.subjectImmunohistochemistry
dc.subjectSma
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectDermatology
dc.subjectPathology
dc.titleCd56 and smooth muscle actin immunoreactivity in basal cell carcinomas: Are they indicators of differentiation or do they hold a diagnostic use?
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication80df1863-762d-4cc1-9313-2d77d9e79ff8
relation.isAuthorOfPublication11cb580f-980e-4dde-92c5-66e7ea4cddaf
relation.isAuthorOfPublication.latestForDiscovery80df1863-762d-4cc1-9313-2d77d9e79ff8

Files

Collections